Profile data is unavailable for this security.
About the company
Vetoquinol SA is a France-based company that specializes in the research, development, manufacture, marketing and sale of veterinary drugs and products. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The Company markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. It trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
- Revenue in EUR (TTM)532.39m
- Net income in EUR59.96m
- Incorporated1962
- Employees2.50k
- LocationVetoquinol SASainte-Anne 34 rue du CheneBp 189, Lure CedexLURE 70204FranceFRA
- Phone+33 384625555
- Fax+33 384625556
- Websitehttps://www.vetoquinol.com/fr
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 381.50m | 28.56m | 1.02bn | 6.13k | 35.59 | 1.77 | -- | 2.66 | 0.4136 | 0.4136 | 5.50 | 8.33 | 0.459 | 2.03 | 5.49 | 510,570.90 | 3.29 | 5.72 | 4.42 | 8.14 | 67.90 | 72.85 | 7.18 | 9.42 | 1.73 | 47.38 | 0.0006 | 18.39 | -19.86 | -3.11 | -15.58 | -5.02 | -0.5518 | -- |
| Nanjing Vazyme Biotech Co Ltd | 163.82m | -3.61m | 1.02bn | 2.87k | -- | 2.18 | -- | 6.23 | -0.0817 | -0.0817 | 3.98 | 9.66 | 0.2715 | 1.10 | 2.75 | 468,919.20 | -0.6649 | 9.69 | -0.8034 | 11.88 | 68.89 | 69.81 | -2.45 | 20.70 | 3.34 | -- | 0.1832 | 35.88 | 7.15 | 38.71 | 74.50 | -- | 30.38 | -- |
| Neuren Pharmaceuticals Ltd | 137.28m | 89.49m | 1.02bn | -- | 11.76 | 5.17 | 11.41 | 7.44 | 1.14 | 1.14 | 1.76 | 2.60 | 0.8175 | -- | 12.92 | -- | 53.29 | 49.68 | 54.95 | 56.56 | -- | -- | 65.19 | 58.60 | -- | 63.36 | 0.00 | 0.00 | -5.63 | 202.59 | -9.57 | -- | -3.58 | -- |
| Kaken Pharmaceutical Co Ltd | 415.86m | -21.06m | 1.02bn | 1.13k | -- | 1.09 | -- | 2.46 | -97.11 | -97.11 | 1,980.56 | 3,850.39 | 0.4091 | 1.86 | 2.80 | 67,195,380.00 | -2.07 | 5.99 | -2.42 | 6.87 | 53.09 | 56.17 | -5.06 | 12.91 | 3.21 | -- | 0.0257 | 59.58 | 30.52 | 1.05 | 73.77 | -6.36 | 14.81 | 0.00 |
| DBV Technologies SA | 3.20m | -103.24m | 1.03bn | 109.00 | -- | 7.03 | -- | 320.46 | -0.9516 | -0.9516 | 0.0296 | 0.531 | 0.0295 | -- | 0.2091 | 29,103.16 | -95.23 | -53.19 | -135.74 | -65.71 | -- | 92.99 | -3,225.05 | -1,296.09 | -- | -172.41 | 0.082 | -- | -73.61 | -22.35 | -56.96 | -- | -16.00 | -- |
| Vetoquinol SA | 532.39m | 59.96m | 1.03bn | 2.50k | 17.09 | 1.81 | 12.20 | 1.94 | 5.10 | 5.10 | 45.25 | 48.20 | 0.7434 | 2.00 | 5.83 | 212,870.50 | 8.37 | 7.52 | 10.34 | 9.96 | 53.16 | 61.63 | 11.26 | 9.54 | 2.13 | -- | 0.0303 | 16.72 | 1.88 | 6.37 | 5.62 | 15.47 | 4.29 | 18.56 |
| Bonesupport Holding AB | 105.92m | 14.38m | 1.05bn | 143.00 | 73.38 | 13.41 | 68.12 | 9.88 | 2.29 | 2.29 | 16.83 | 12.52 | 1.26 | 0.6205 | 6.26 | 8,811,984.00 | 17.06 | 5.14 | 20.11 | 6.31 | 92.61 | 91.40 | 13.57 | 5.59 | 3.92 | 19.36 | 0.0133 | 0.00 | 52.05 | 42.04 | -45.41 | -- | 5.71 | -- |
| Frontier Biotechnologies Inc | 17.21m | -20.44m | 1.05bn | 302.00 | -- | 8.79 | -- | 61.09 | -0.4478 | -0.4478 | 0.377 | 2.62 | 0.0775 | 1.78 | 2.74 | 467,559.50 | -9.21 | -12.65 | -12.08 | -14.50 | 32.51 | 18.59 | -118.79 | -333.96 | 2.58 | -- | 0.3472 | -- | 13.32 | 44.07 | 38.78 | -- | -35.01 | -- |
| Alivus Life Sciences Ltd | 233.24m | 50.48m | 1.06bn | 2.20k | 21.01 | -- | 18.55 | 4.54 | 44.23 | 44.23 | 204.37 | -- | -- | -- | -- | 11,403,810.00 | -- | 17.43 | -- | 23.95 | 57.08 | 53.29 | 21.64 | 20.24 | -- | 133.39 | -- | 27.09 | 4.54 | 9.20 | 3.13 | 9.18 | 26.57 | -- |
Data as of Feb 12 2026. Currency figures normalised to Vetoquinol SA's reporting currency: Euro EUR
10.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 388.98k | 3.27% |
| Oddo BHF Asset Management SASas of 31 Dec 2025 | 183.18k | 1.54% |
| BNP Paribas Asset Management Europe SASas of 31 Dec 2025 | 113.72k | 0.96% |
| Invesco Advisers, Inc.as of 31 Dec 2025 | 96.27k | 0.81% |
| Lazard Fr�res Gestion SASas of 31 Dec 2025 | 81.43k | 0.69% |
| Janus Henderson Investors UK Ltd.as of 31 Dec 2025 | 78.50k | 0.66% |
| Danske Bank A/S (Investment Management)as of 31 Jan 2026 | 77.35k | 0.65% |
| HC Capital Advisors GmbHas of 31 Oct 2025 | 74.75k | 0.63% |
| Cr�dit Mutuel Asset Management SAas of 31 Dec 2024 | 71.38k | 0.60% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 61.96k | 0.52% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
